Indirubin is an active ingredient of a traditional Chinese medicine (TCM) named "Danggui Longui Wan," which has potent activity against myelocytic leukemia. 1, 2 Indirubin is the purple component of the dye indigo blue, which is extracted from plants such as Polygonum tinctorium Lour and Indigofera tinctoria. Indirubin is a 3,2'-bisindole, a stable isomer of indigo (Fig. 1) .
Indirubin has anti-inflammatory and anti-cancer activities. Kunikata et al. reported that indirubin inhibits inflammatory reactions in delayed-type hypersensitivity in mice. 3 They described the effects of indirubin on cytokine production by immunocompetent cells and on the delayed-type hypersensitivity reaction in vitro, in which interferon-γ has a crucial role. Mak et al. reported that indirubin suppresses expression of the influenza virus-induced chemokine RANTES in human bronchial epithelial cells. 4 Moreover, indirubin has shown potent anti-proliferative activity in various human cancer cells. 5 In a recent prospective study, Sugimoto et al. reported that the Chinese herbal medicine "Qing-Dai," (which contains indole compounds, including indirubin) was effective for patients with ulcerative colitis (UC), which is involved in inflammatory bowel disease (IBD). 6 Oral administration of the sulfated polysaccharide dextran sulfate sodium (DSS) induces colitis in mice, 7, 8 rats, 9 guinea pigs, 10 and hamsters. 11 Okayasu et al. reported a UC model involving oral administration of DSS in BALB/c and CBA/J mice. 7 Depending on the time-course of oral administration of DSS in drinking water, it could induce acute or chronic colitis in mice. 7 DSS-induced colitis exhibits several morphologic and pathophysiologic features similar to those observed in human IBD, including production of cytokines and other inflammatory mediators, as well as leukocyte infiltration. 7, 8, 12 A DSS-induced model of colitis in animals has been used to examine the effect of various anti-inflammatory agents against IBD. [13] [14] [15] [16] [17] Herein, we examined the effect of indirubin on DSS-induced colitis in mice. We showed, for the first time, that indirubin treatment can improve murine DSSinduced colitis.
MATERIALS AND METHODS

Animals
Female BALB/c mice (6 weeks; 20-22 g) were obtained from Charles River Japan (Kanagawa, Japan). The mice were treated in accordance with the Guidelines for Animal Experimentation set by Tottori University (06-S-76) (Tottori, Japan). Animals were housed in rooms at a controlled temperature of 24 ± 2 °C and light-dark cycle with a maximum of six mice per cage. Mice were fed with standard pellets (MF; Oriental Yeast, Tokyo, Japan) and had free access to drinking water. Chemicals DSS (molecular weight: 36,000-50,000) was purchased from ICN Biomedicals (Eschwege, Germany). Indirubin was synthesized by Asahi Kasei Finechem (Osaka, Japan). 18 
Induction of colitis and treatment with indirubin
Acute colitis was induced with 2% DSS given in drinking water for ≤ 6 days (n = 12). Mice were treated with indirubin (0.05 μg/ g/day) in their diet (n = 6). Mice not given In acute-colitis studies, mice were subjected to one, 6-day DSS cycle. Mice were fed a normal or indirubin-supplemented diet, commencing 5 days before the start of the experiment and continuing until the end of the experiment. Mice were killed on day-6 (arrow). (B) For the study of chronic colitis, mice were subjected to three consecutive DSS cycles. Each cycle consisted of a DSSadministration period followed by a recovery period in which water was administrated. Mice were fed a normal or indirubin-supplemented diet commencing 5 days before the start of the experiment and continuing until the end of the third DSS cycle. All surviving mice were killed at the completion of the third DSS cycle (arrow). DSS, dextran sulfate sodium.
DSS or indirubin were used as the control group (n = 6). Chronic colitis was induced by administration of 2% DSS in three cycles for 6 days, interspersed with 8 days of giving drinking water (n = 12). Mice were treated with indirubin (0.05 μg/g/day) in their diet (n = 6). Mice not given DSS or indirubin were used as the control group (n = 6). Indirubin treatment was started before the 5 days of DSS exposure and continued throughout the observation period in acute and chronic models of colitis (Fig. 2) .
Evaluation of colitis and drug effects
General parameters recorded in the experiments were body weight and food consumption. After the end of the experiment, all mice were killed by cervical dislocation. Immediately, large intestines were resected between the ileocecal junction and proximal rectum. The length of the large intestine was measured to evaluate the preventive effect of indirubin treatment on shortening of the large intestine accompanied by colitis. Large intestines were placed on filter papers to measure their length, after which they were opened longitudinally so that their contents could be removed.
The colon was divided into two equal segments (proximal and distal) and fixed in neutral-buffered 10% formalin. All slides were stained with hematoxylin and eosin. For histopathologic evaluation of tissue damage, areas of inflammatory lesions were evaluated under light microscopy and quantified using the method of Cooper et al., 8 with minor modifications (Table 1) . Grading was based on pathologic changes: 0, intact crypt; 1, loss of the basal one-third of the crypt; 2, loss of the basal twothirds of the crypt; 3, loss of the entire crypt with the surface epithelium remaining intact; 4, loss of the entire crypt and surface epithelium (erosion). These changes were quantitated according to percentage involvement by the disease: (1) 1-25%; (2) 26-50%; (3) 51-75%; (4) 76-100%. Each section was scored with a grade and percentage area involvement, with the product of the two being a "crypt score." The scores for each tissue were summed and divided by the number of pieces of tissue to give a "histology score." Colitis was not observed in the proximal colon, so only the distal colon was evaluated in all cases. The distal colon was divided into 4 sections and evaluated.
For histologic evaluation of the extent of fibrosis in the submucosa, all slides were stained with Masson's trichrome. The extent of fibrosis per 1-cm of the distal colon was calculated as "percentage involvement." Mast cells were identified by staining (toluidine blue) (Fig. 3) . The number of mucosal toluidine blue-positive cells in the distal colon was counted, and number per 1-cm was calculated. After killing, the rectum (5 mm × 5 mm) was excised. Feces were removed by gentle washing in physiologic (0.9%) saline. The rectum tissue was homogenized and the concentration of the interleukin (IL)-6 level in the supernatant was measured by sandwich ELISA using paired antibodies according to manufacturer (RayBio, Norcross, GA) recommendations.
Statistical analyses
Data are the mean ± standard deviation (SD). Data comparisons were made using the Student's t-test and Pearson correlation to test the correlation between variables. P < 0.05 was considered significant.
RESULTS
Mice administered only indirubin (0.05 μg/g/day) in their diet for 1 month suffered no pathologic change, compared with the control group, in terms of body weight, colonic histology, and IL-6 content in the rectum (data not shown).
General features Acute colitis
There was no difference in consumption of DSS-water between the groups given and not given indirubin in acute and chronic models of colitis. Administration of 2% DSS for 6 days resulted in severe colitis with a significant reduction in body weight and food intake from day-4. On the final day of observation, the mean increase in body weight was 0.44 ± 2.1 g in mice not given indirubin, and 1.67 ± 0.5 g in mice given indirubin, and this difference was significant (P = 0.03) [ Fig. 4A ]. The mean food intake per mouse per day was 4.80 ± 1.0 g in mice not given indirubin, and 4.36 ± 0.58 g in mice given indirubin, but the difference was not significant (P = 0.31). The length of the large intestine was 13.4 ± 0.58 cm in mice not given DSS or indirubin (control), 10.2 ± 0.52 cm in colitis mice not given indirubin, and 11.1 ± 0.58 cm in colitis mice given indirubin (Fig. 5A) . Thus, indirubin showed a significant preventive effect on shortening of the large intestine in our model of acute colitis (P = 0.02) [ Fig. 5A ].
Chronic colitis
Stable chronic colitis could be achieved by three repeat 6-day cycles of DSS interrupted by 8-day recovery periods using water not containing DSS. Initially, mice manifested diarrhea and blood in feces and body-weight loss in the first cycle of administration of 2% DSS. However, these signs improved after drinking water for the next 8 days. On subsequent administrations of DSS (three cycles), these symptoms improved during the 8-day period of water consumption (Fig. 4B) . Only one mouse receiving 2% DSS without indirubin died with severe loss of body weight (16.1 g) on day-18. On the final day of observation, the mean body weight increased from 2.76 ± 0.4 g in mice not given indirubin to 3.53 ± 1.1 g in mice given indirubin, and this difference was not significant (P = 0.18) [Fig. 4B ]. The mean food intake per mouse per day was 5.31 ± 1.7 g in mice not given indirubin, and 4.64 ± 1.6 g in mice given indirubin, and this difference was not significant (P = 0.11). The length (mean ± SD) of the large intestine was 12.9 ± 0.75 cm in mice not given DSS and indirubin (Fig. 5B) . Thus, indirubin prevented a significant reduction in colon length in the chronic-colitis model (P = 0.003).
Histology
Acute colitis
Representative histologic findings are shown in Figs. 6A-C. DSS induced erosive colitis in a variable manner (Fig. 6B ). The histology score was 8.83 ± 2.2 in acute-colitis mice not given indirubin and 5.16 ± 2.4 in acute-colitis mice given indirubin, and this difference was significant (P = 0.02) [Fig. 7A ]. The extent of submucosal fibrosis was 40.4 ± 8.9% in mice not given indirubin and 22.2 ± 13% in mice given indirubin, and this difference was significant (P = 0.018). The histology score correlated well with body-weight reduction according to the Pearson's correlation coefficient test (r = 0.62). Administration of 2% DSS for 6 days resulted in a marked increase in the number of mucosal toluidine blue-positive cells. The number of mucosal toluidine blue-positive cells was 334 ± 64/cm in mice not given indirubin and 163 ± 89/cm in mice given indirubin, and this difference was significant (P = 0.004).
Chronic colitis
The histology score was 6.40 ± 0.89 in chronic-colitis mice not given indirubin and 5.16 ± 2.0 in chronic-colitis mice given indirubin, and this difference was not significant (P = 0.24) [Fig. 7B ]. The extent of submucosal fibrosis was 28.0 ± 11.8% in mice not given indirubin and 36.7 ± 19.2% in mice given indirubin, and this difference was not significant (P = 0.40). The histology score did not correlate well with body-weight reduction according to the Pearson's correlation coefficient test (r = 0.21).
The number of mucosal toluidine blue-positive cells was 138 ± 109/cm in mice not given indirubin and 129 ± 77/cm in mice given indirubin, and this difference was not significant (P = 0.88).
Changes in levels of pro-inflammatory cytokines
We measured IL-6 content in the rectum of mice in the presence and absence of indirubin at day-6. The IL-6 level was 541 ± 728 pg/mL in the rectum of mice not given indirubin and 154 ± 217 pg/mL in mice given indirubin, and this difference was not significant (P = 0.24) in acute colitis [ Fig. 8A ]. The IL-6 level was 69.6 ± 14.2 pg/mL in the rectum of mice not given indirubin and 28.4 ± 13.1 pg/mL in mice given indirubin, and this difference was significant (P = 0.001) in chronic colitis [ Fig. 8B ]. Serum levels of IL-6 were not detected in mice suffering from acute or chronic colitis.
DISCUSSION
IBD includes the common gastrointestinal diseases UC and Crohn's disease, and their incidence is increasing worldwide. Therapies such as mesalamine, corticosteroids, and thiopurines, in general, provide only transient or marginal relief, so the development of alternative treatments is of great interest. TCM, which is based to a large extent on the use of plant extracts, constitutes a valuable approach for the discovery of new drugs. A recent clinical trial showed that the Chinese herbal medicine Qing-Dai (which contains indirubin) was effective for inducing remission in patients with UC. 6 Dr. Amano (Hiroshima, Japan) has treated more than 4500 patients with intractable UC using QingDai. The latter is extracted from the leaves and stems of plant species such as Baphicacanthus cusia (Nees) Bremek. (Acanthaceae), Polygonum tinctorium Ait. (Polygonaceae), and Isatis indigotia Fort. (Cruciferae). Qing-Dai contains several organic components such as indigo, indirubin, tryptanthrin, sterols, and amino acids. 19 Indirubin is a well-known TCM used for the treatment of myelocytic leukemia. Several clinical trials using indirubin have been undertaken for the treatment of chronic myelocytic and chronic granulocytic leukemia in China. [20] [21] [22] [23] In one study undertaken by the Cooperative Group of Clinical Therapy of Indirubin, 26% of 314 patients with chronic myelocytic leukemia showed complete remission, and 33% showed partial remission, in response to indirubin treatment. 21 Toxicity was low and side effects were limited to mild abdominal pain, diarrhea, nausea and vomiting. There were three cases of reversible pulmonary arterial hypertension and cardiac insufficiency. 24 Indirubin exhibits only minor toxicity in animal models. 25 For example, dogs given a dose of indirubin 25-times that used for human therapy (according to body weight) continuously for 6 months showed diarrhea and some damage to the liver, with no change in hematopoiesis, electroencephalographic activity or renal function. 26 In our animal study, indirubin treatment for 1 month did not elicit unfavorable clinical or histologic changes in mice not given DSS (data not shown). Therefore, the therapeutic effect of indirubin can be examined without inducing toxicity in clinical studies.
Among the various models of chemically induced colitis, the DSS-induced colitis model is used widely because of its simplicity and many similarities with human UC. This model has advantages and disadvantages that must be considered when employed. 27 Mice show different susceptibilities and responsiveness to DSSinduced colitis. Several mechanisms for DSS colitis have been proposed. In one representative mechanism, DSS administration blocks bacterial phagocytosis by macrophages in the lamina propria and causes direct injury to the epithelium, leading to early shortening and erosions in crypts. 28, 29 Varying responses to DSS appear to be dependent on the inbred strain, 30 DSS concentration, 31 molecular weight of DSS, 32 and duration of DSS exposure. 8 In our study, significant differences in the consumption of DSS-water were not observed between groups given or not given indirubin. We, therefore, concluded that consumption of DSS-water did not affect the severity of DSS-induced colonic injury in mice. Kitajima et al. reported that the severity and primary location of colitis differ depending upon the molecular weight of DSS administered in mice. Colitis was observed predominantly in the cecum and upper colon in mice given DSS of molecular weight 5 kD. In mice given DSS of molecular weight 40 kD, colitis was more prominent in the distal colon. 32 In our study, colitis was localized to the distal colon in all mice because DSS of molecular weight 36-50 kD was used for oral administration. A histology grading system showed that indirubin improved DSS-induced acute colitis, but was not prominent in the chronic-colitis model. In the latter, the region with crypt loss had been displaced with epithelial dysplasia. Therefore, there might not be significant differences in histology grades between mice given DSS and those not given DSS. Histology demonstrated collagen accumulation in the submucosal region of intestines, which could be the cause of intestinal shortening in the colitis model. Smooth muscle cells, subepithelial myofibroblasts, and fibroblasts have been considered to be the mediators of fibrosis, but new evidence points to a role for interstitial mast cells. 33 We did not observe a significant difference in collagen production, but colon length was significantly shorter in the chronic-colitis model. Graham et al. reported that the thickness of the muscularis propria is also increased in colitis, 34 which might also result in shortening of the intestine wall. Indirubin might have an effect on controlling the thickness of the muscularis propria in the chronic-colitis model.
Pro-inflammatory cytokines have been demonstrated to have a crucial role in IBD pathogenesis. Among these cytokines, higher expression of IL-6 has been demonstrated repeatedly. 35 Naito et al. reported that DSS-induced inflammation appears to be inhibited significantly in IL-6 −/− mice compared with wild-type mice. They suggested that persistent and marked blockade of IL-6 bioactivity provides some beneficial effects against intestinal inflammation. 36 A clinical trial carried out recently in Japan clearly demonstrated the beneficial effects of humanized anti-IL-6 monoclonal antibody for treatment-resistant active Crohn's disease. 37 In our study, indirubin obviously suppressed the tissue level of IL-6 in acute and chronic models of colitis, with a significant effect being observed in the chronic-colitis model. This finding could imply the crucial role of IL-6 in suppressing DSS-induced colitis. Further studies are needed to clarify the precise relationship between indirubin and IL-6. Recently, Kawai et al. showed that Indigo naturalis and its major component indigo ameliorated murine DSS-induced colitis via upregulation of expression of IL-10 and IL-22 through activation of the aryl hydrocarbon receptor. 38 Further studies are needed to clarify the mechanisms of action of indirubin in preventing UC pathogenesis.
We clearly proved that oral intake of indirubin can improve murine DSS-induced colitis (which mimics human IBD). 39 Furthermore, we showed, for the first time, that indirubin is more effective in the acute phase than in the chronic phase.
